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Abstract Protein phosphatase 4 (PP4) is a protein serine/
threonine phosphatase that predominantly localises to centro-
somes and plays a role in microtubule organisation at centro-
somes. Here, PP4 catalytic subunit has been purified from
porcine testis to near homogeneity and a specific activity of 680
mU/mg against phosphorylase a. The antitumour drug, fostrie-
cin, inhibits PP4 catalytic subunit (IC50 3 nM) with similar
potency to PP2A catalytic subunit (IC50 1.5 nM). PP4 is also
inhibited in the nanomolar range by several naturally occurring
tumour promoters and toxins, with similar IC50 values to those
obtained for PP2A. The gene for human PP4 catalytic subunit
localises to 16p11.2.
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1. Introduction
Reversible phosphorylation of serine and threonine residues
is a major mechanism for regulation of cellular processes in
eukaryotes. Protein phosphatase 4 (PP4, formerly termed
PPX) is a member of the PPP family of protein serine/threo-
nine phosphatases, which includes PP1, PP2A, PP2B (calci-
neurin) and PP5 [1,2]. Although most closely related to PP2A
with 65% amino acid sequence identity, PP4 does not bind the
65 kDa regulatory subunit [3] that forms a tight complex with
PP2A catalytic subunit [4]. Furthermore PP4 and PP2A are
immunocytologically and functionally distinct. Although PP4
is present in the nucleus and more weakly in the cytoplasm,
antibodies to PP4 (but not those against PP2A) intensely stain
centrosomes in mammalian and Drosophila cells and in Dro-
sophila embryos [4,5]. A Drosophila mutant carrying a P ele-
ment in the PP4 gene and possessing reduced levels of PP4
protein in the embryo shows a semi-lethal phenotype, in
which microtubule organisation at centrosomes is disrupted,
implicating PP4 in the initiation of microtubule growth [5]. In
contrast Drosophila de¢cient in PP2A catalytic subunit exhibit
a lethal phenotype in which long microtubules radiate from
centrosomes but are unconnected to the chromosomes [6].
PP2A (or a closely related okadaic acid sensitive phosphatase)
has also been shown to dephosphorylate stathmin/Op18 and
thereby maintain a shorter steady-state length of microtubules
in vitro [7].
Fostriecin, a novel antitumour antibiotic isolated from
Streptomyces pulveraceus (subspecies fostreus) [8,9] has anti-
neoplastic activity on a wide spectrum of tumour cells in vitro
and against L1210 and P388 murine leukaemias in vivo
[10,11]. Currently, fostriecin is being evaluated as an anti-
cancer drug in human clinical trials [12]. Early studies showed
that a possible target of fostriecin was topoisomerase II which
is inhibited with an IC50 of 40 WM [13]. However, more recent
studies suggest that the antitumour activity of fostriecin may
reside in the more potent inhibition of the protein serine/
threonine phosphatases PP2A and PP1. Enhanced histone
2A and 3 phosphorylation is associated with fostriecin in-
duced chromosome condensation, and hyperphosphorylation
of vimentin in response to fostriecin correlates with intermedi-
ate ¢lament reorganisation [14^16]. While the IC50 of fostrie-
cin for PP1 was found to be in the micromolar range, the
antitumour agent inhibited PP2A with an IC50 in the nano-
molar range [15,17]. These ¢ndings raise the question of
whether fostriecin at nanomolar concentrations is speci¢c
for inhibition of PP2A or whether it also inhibits related
phosphatases, such as PP4. Since PP4 cannot be assayed in
cell extracts, we have puri¢ed the native PP4 catalytic subunit
to near homogeneity from porcine testis and we show that
PP4, like PP2A, is inhibited by nanomolar concentrations of
fostriecin.
2. Materials and methods
2.1. Materials
The PP2A catalytic subunit and the trimeric PP2A1 complex [18]
were puri¢ed to homogeneity from bovine heart by Dr S. Hawley and
Dr N. Morrice, University of Dundee. Human PP1Q1 [19] was ex-
pressed in Escherichia coli and puri¢ed as described in [20]. Fostriecin
was generously donated by the Drug Synthesis and Chemistry Branch,
Developmental Therapeutics Program, Division of Cancer Treatment,
National Cancer Institute, Bethesda, MD, USA. Okadaic acid was a
gift from Dr Y. Tsukitani, Fugisawa Pharmaceutical Company, To-
kyo and tautomycin was provided by Dr K. Isona, Institute of Phys-
ical and Chemical Research, Saitama, Japan. Microcystin-LR was
prepared by Dr L. Lawton, Robert-Gordons University, Aberdeen,
UK. Cantharidin was purchased from Calbiochem, Nottingham, UK
and calyculin A from Life Technologies, Paisley, UK.
2.2. Puri¢cation of PP4 catalytic subunit from porcine testis
Freshly excised porcine testes were placed on ice at the slaughter-
house. All subsequent steps were performed at 0^4‡C, except the fast
protein liquid chromatography separations were at room temperature.
Ten porcine testes (4 kg) were decapsulated after 20 min on ice,
minced and homogenised in 1 volume bu¡er A (50 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 0.1 mM EGTA, 0.03% (v/v) Brij-35, 0.1%
(v/v) 2-mercaptoethanol) containing 0.1 mM phenylmethylsulphonyl
£uoride and 1 mM benzamidine then centrifuged at 4200Ug for 30
min. The supernatant was ¢ltered through glass wool and subjected to
a 10^30% ammonium sulphate precipitation. The pellet was resus-
pended in 1 litre bu¡er A, dialysed against bu¡er A overnight and
centrifuged for 20 min at 100 000Ug. The supernatant was poured
through a Buchner funnel containing 20 g of QAE-Sephadex equili-
brated in bu¡er A. The column was washed with 1 litre of bu¡er A
containing 0.1 M NaCl and PP4 eluted with 1.5 litres bu¡er A con-
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taining 0.4 M NaCl. Solid ammonium sulphate was added to the
eluate to bring the ¢nal concentration to 40% saturation. After stir-
ring for 30 min, the suspension was centrifuged for 30 min at 4200Ug.
The pellet resuspended in 100 ml bu¡er A containing 5% (v/v) glycerol
(bu¡er B) and dialysed against bu¡er B overnight. The dialysate was
centrifuged for 20 min at 100 000Ug and the supernatant chromato-
graphed on a HiLoad 16/10 Q-Sepharose column equilibrated in bu¡-
er B. The column was developed with a 300 ml linear gradient of
NaCl from 0.1 M to 0.5 M at a £ow rate of 5 ml/min and 5 ml
fractions collected. Fractions eluting between 265 and 330 mM
NaCl containing PP4 (detected here and at subsequent stages by im-
munoblotting) were pooled, dialysed into bu¡er B, applied to a 5 ml
HiTrap Q-Sepharose column equilibrated in bu¡er B and concen-
trated by elution with 8 ml of 0.5 M NaCl. The eluate was dialysed
against bu¡er C (50 mM MOPS (pH 7), 1 mM EDTA, 0.1 mM
EGTA, 0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoethanol, 5% (v/v)
glycerol) and applied to a 5 ml HiTrap heparin-Sepharose column
equilibrated in bu¡er C. The £owthrough containing PP4 was applied
to a 5 ml HiTrap SP-Sepharose column equilibrated in bu¡er C.
Again, the £owthrough containing PP4 was dialysed against bu¡er
B and chromatographed on a HR 5/5 Mono-Q column equilibrated
in bu¡er B. The column was developed with a 25 ml 0^0.5 M NaCl
linear gradient at a £ow rate of 1 ml/min and 0.5 ml fractions col-
lected. Fractions containing PP4 eluting at 250^300 mM NaCl were
pooled, concentrated to 200 Wl in a Centricon-30 and subjected to gel
¢ltration on a HR 10/30 Superose 6 column equilibrated in bu¡er B
containing 0.4 M NaCl. The peak PP4 fractions were concentrated to
200 Wl in a Centricon-30 and subjected to gel ¢ltration on a HR 10/30
Superose 12 column equilibrated in bu¡er B containing 0.4 M NaCl.
Fractions containing PP4 were snap frozen in liquid nitrogen and
stored at 370‡C.
2.3. Immunoblotting
Protein extracts were fractionated by 10% polyacrylamide/sodium
dodecyl sulphate gel electrophoresis and stained for protein using
silver stain [21] or transferred to nitrocellulose and probed with 0.1
Wg/ml a⁄nity puri¢ed anti-PP4 antibodies. Antibody binding was de-
tected using anti-sheep IgG antibodies conjugated to horseradish per-
oxidase, followed by enhanced chemiluminescence (Amersham, UK).
Rabbit PP4 expressed in E. coli [4] was used as a control on immu-
noblots. Anti-PP4 antibodies were raised against bacterially expressed
glutathione S-transferase (GST) fused to the N-terminal 57 amino
acids of human PP4 and a⁄nity puri¢ed against bacterially expressed
PP4 by Dr N. Helps. Anti-PP6 antibodies were produced against
bacterially expressed GST fused to the N-terminal 55 amino acids
of Drosophila PPV 6A (homologue of mammalian PP6) and a⁄nity
puri¢ed against the N-terminal 55 amino acids by Dr H. Snaith. Anti-
PP1 antibodies were raised and a⁄nity puri¢ed against PP1Q. Anti-
bodies were raised in sheep at the Scottish Antibody Production Unit,
Carluke, Lanarkshire, UK. After a⁄nity puri¢cation they detected
9 1 ng of their respective antigen and the appropriate phosphatase
band in mammalian tissue extracts. Anti-PP2A antibodies were from
Promega Corp., Madison, WI, USA, and detected 9 0.1 ng PP2A
catalytic subunit.
2.4. Protein phosphatase assays
Rabbit skeletal muscle glycogen phosphorylase (prepared by Ms F.
Douglas) was 32P-labelled by phosphorylase kinase to a stoichiometry
of 1 mol phosphate per mol subunit as in [18] by Dr L. Tung and was
used at 10 WM in the assays. Partially hydrolysed bovine casein was
phosphorylated by cyclic AMP-dependent protein kinase (PKA) to
3.5 nmol phosphate per mg protein [22] and was present at 6 WM in
the assays. Protein phosphatase assays were performed in the absence
of divalent cations [18], except for PP1Q assays which contained 1 mM
Mn2. One unit of activity is the amount of enzyme which catalyses
the release of 1 Wmol of [32P]phosphate per minute. Inhibitors were
incubated with the phosphatase diluted in the assay bu¡er for 10 min
prior to the addition of substrate. Fostriecin was dissolved in phos-
phate bu¡ered saline containing 0.1 mM ascorbic acid. Okadaic acid,
cantharidin, calyculin A and tautomycin were dissolved in dimethyl
sulphoxide and microcystin in methanol. All inhibitors were diluted in
assay bu¡er immediately before use. At these dilutions, none of the
solvents or the phosphate bu¡ered saline containing 0.1 mM ascorbic
acid inhibited any of the phosphatases.
2.5. Human gene mapping
DNA from human-rodent hybrid somatic cell lines with chromo-
some contents described in [23,24] was analysed for the presence of
the PP4 gene by the polymerase chain reaction (PCR). Human PP4-
speci¢c oligonucleotides encoding amino acids 177^184 and comple-
mentary to nucleotides encoding amino acids 224^233 were used to
amplify a section of the PP4 coding region, which contained an intron
[25]. The PCR reactions were analysed by gel electrophoresis and
ethidium bromide staining, followed by Southern blotting and hybrid-
isation with the 32P-labelled oligonucleotide complementary to nucleo-
tides 642^665 encoding amino acids 216^222.
32P-Labelled human PP4 cDNA [25] was used to screen a yeast
arti¢cial chromosome (YAC) library constructed from human lym-
phoblastoid cell line DNA [26,27]. Three positive YAC clones were
analysed further by PCR with PP4-speci¢c oligonucleotides which
con¢rmed that all three contained the human PP4 gene. Genomic
DNA from one PP4 positive YAC clone was used for £uorescent in
situ hybridisation to human metaphase chromosomes.
3. Results
3.1. Isolation of a native active protein phosphatase 4 catalytic
subunit from porcine testis
There is no speci¢c assay for PP4 that can distinguish it
from many other members of the PPP family, and therefore
PP4 was detected throughout the puri¢cation with anti-PP4-
speci¢c antibodies. Table 1 shows the 3100-fold puri¢cation of
PP4 catalytic subunit from porcine testes, the amounts of PP4
at each step being estimated semi-quantitatively by immuno-
blotting using known quantities of bacterially expressed PP4
as standards. The ¢nal puri¢cation step was gel ¢ltration on
Superose 12 which showed that PP4 eluted essentially as a
single silver stained band in fractions 71 and 72 (Fig. 1 shows
fraction 72) with an apparent molecular mass of 35 kDa,
indicating that the free catalytic subunit was a monomer. A
symmetrical peak of phosphorylase phosphatase activity was
observed (Fig. 1, top panel). Digestion of the 35 kDa band
with trypsin and examination of the peptides by matrix-assist-
ed laser desorption/ionisation mass spectrometry (performed
by Dr N. Morrice) con¢rmed that it was indeed PP4. The
speci¢c activities of porcine PP4 in fractions 70, 71 and 72
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Table 1
Puri¢cation of protein phosphatase 4 catalytic subunit from porcine testis
Step Total protein Total PP4 Puri¢cation Yield
(mg) (Wg) (fold) (%)
Extract 110 000 28 000 1 100
10^30% ammonium sulphate fractionation 30 000 10 000 2 36
QAE-Sepharose 3 000 4 000 5 15
Q-Sepharose 550 1 300 10 4.6
Heparin and SP-Sepharose 155 1 200 31 4.3
Mono-Q 70 900 52 3.2
Superose 6 (fr. 89^93) 1.2 300 1000 1.1
Superose 12 (fr. 70^72) 0.11 85 3100 0.3
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were 400, 680 mU/mg and 500 mU/mg towards phosphorylase
respectively, and the average speci¢c activity of porcine PP4 in
fractions 70^72 was 530 mU/mg using phosphorylase and 420
mU/mg using casein as substrate. Immunoblotting of PP4
fractions from the Superose 6 column showed that they
were free of PP1, PP2A and PP6 (data not shown).
3.2. Inhibition of PP4 by tumour suppressors and tumour
promoters
Native porcine PP4 catalytic subunit, assayed using phos-
phorylase as substrate, was inhibited by the antitumour drug
fostriecin with an IC50 of 3 nM, while the IC50 for the native
PP2A catalytic subunit (Fig. 2) and the PP2A1 complex was
1.5 nM (data not shown). Similar results were obtained with
casein as substrate, the IC50 of PP4 for fostriecin being 3 nM
(data not shown). In contrast the IC50 of PP1Q for fostriecin
was 45 WM with phosphorylase as substrate. Inhibition of PP4
by several other tumour suppressors, promoters or toxins was
also virtually identical to that observed with PP2A (Fig. 2).
PP4 was inhibited by okadaic acid, microcystin-LR, calyculin
A tautomycin, and cantharidin with an IC50 of 0.1 nM, 0.15
nM, 0.2 nM, 0.4 nM and 50 nM, respectively.
3.3. Mapping of the PP4 gene in the human genome
An approximately 0.7 kb PP4-speci¢c band was detected in
human but not in rodent (rat, hamster or mouse) DNA by
PCR using human PP4-speci¢c primers followed by hybrid-
isation with a PP4-speci¢c probe. Rodent-human somatic cell
hybrid DNA from cell lines Dur4R3, Dur4.3, Horp 27RCL4,
SIRii, FG10, 1KA9, HM76Dd, Fst9/10, MCP6, 5647Cl22,
SIF4A31, TWIN19D12, Mog3.4.A4, LSR8, 2860H7 and
Mog13/22 was analysed similarly by PCR and showed that
the presence of the 0.7 kb human PP4-speci¢c product was
concordant with the presence of chromosome 16. Since the
somatic cell hybrid Mog13/22 contained only the short arm
of chromosome 16 (in addition to chromosomes 1, 22 and X),
this localised the PP4 gene to 16p [28]. A YAC clone contain-
ing PP4 genomic DNA was used to localise the PP4 gene by
£uorescent in situ hybridisation to position 16p11.2 (per-
formed by Ms S. Marsh and Dr N. Carter, The Sanger
Centre, Wellcome Trust Genome Campus, Cambridge).
Although a second weaker signal was seen at 16p12 in some
chromosome spreads, this is probably artifactual since South-
ern blotting of human genomic DNA only revealed a single
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Fig. 2. E¡ect of tumour suppressors/promoters and toxins on pro-
tein phosphatases. Panel A shows the inhibition of PP4, PP2A and
PP1Q by fostriecin. Panels B^F show the inhibition of PP4 and
PP2A by okadaic acid, microcystin-LR, calyculin A, tautomycin
and cantharadin, respectively. PP4 catalytic subunit from Superose
12 fraction 71 (a), PP2A catalytic subunit (F) and PP1Q (O) were
assayed at 0.2 mU/ml using phosphorylase as substrate.
Fig. 1. Puri¢cation of PP4 by gel ¢ltration on Superose 12. A:
Phosphorylase phosphatase activity detected in the Superose 12 frac-
tions. The molecular mass markers were ovalbumin (44 kDa) and
myoblobin (17 kDa). B: Polyacrylamide/sodium dodecyl sulphate
gel electrophoresis of the Superose 12 fractions. Protein bands were
detected using silver stain. The position of PP4 is indicated by an
arrow. Molecular size markers are given in kDa. C: Immunoblot of
the Superose 12 fractions probed with antibodies to PP4.
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band hybridising to the PP4 human cDNA in EcoRI, BamHI
and HindII digests. In addition, a single PP4 gene has been
partially sequenced [29] and the sequence corresponds to the
cDNA sequence described in [25].
4. Discussion
The data presented here show that the antitumour drug
fostriecin is a potent inhibitor of the native PP4 catalytic
subunit with an IC50 of 3 nM. The inhibition is virtually
identical to that observed with PP2A (Fig. 2 and [17]). In
contrast the IC50 of fostriecin for PP1Q was 45 WM (Fig. 2)
and fostriecin was reported to have no e¡ect on PP2B activity
[17]. The mechanism of action of fostriecin as an antitumour
drug could therefore be by inhibition of either PP4, PP2A or
both. No speci¢c in vivo substrates of PP4 are known, but the
fact the fostriecin inhibits PP4 similarly with phosphorylase or
casein (data not shown) indicates that the inhibition is not
likely to be substrate-speci¢c. The results raise the possibility
that fostriecin might act by inhibition of microtubule organ-
isation and dynamics, since both PP4 and PP2A are involved
in the regulation of these processes (see Section 1). Other
antitumour drugs are known to interfere with microtubule
growth or stability [30].
The high a⁄nity binding site of fostriecin would be ex-
pected to lie in the regions of PP2A and PP4 that are identical
to each other but di¡erent from PP1 and PP2B. This may also
be close to the active site, since fostriecin is a phosphate ester
(containing an unsaturated lactone and conjugated triene),
which may occupy the active site as would a phosphorylated
substrate.
Okadaic acid, microcystin, calyculin A and cantharidin
have been reported to promote or suppress tumour formation
depending on the duration of the toxin application or the cell
type (reviewed in [31]). All these toxins and tautomycin are
found to inhibit native PP4 and PP2A at very similar concen-
trations. With the recognition that several members of the
PPP family are inhibited by these toxins, it is possible that
some of the variability of action depends on the relative levels
of the phosphatases in each cell type together with the fact
that each enzyme may regulate several functions. Although
several of these toxins have proved useful in identifying phys-
iological processes that are regulated by reversible protein
serine/threonine phosphorylation and distinguishing which
processes are likely to be controlled by PP1 [32], it is clear
that none of them distinguish PP2A from PP4 (and probably
PP6 as well). Caution must therefore be taken in ascribing a
function to PP2A (or PP4) solely on the basis of inhibition by
these toxins.
Attempts to express PP4 catalytic subunit in E. coli in an
active form have been unsuccessful and the level of expression
of soluble active PP4 catalytic subunit from baculovirus in
insect cells is extremely low [4] making complete separation
from the endogenous insect cell protein serine/threonine phos-
phatases di⁄cult. For these reasons, we decided to purify PP4
catalytic subunit from testis, where the highest levels of PP4
mRNA and protein are found [4,33]. The native PP4 catalytic
subunit puri¢ed here to near homogeneity has a speci¢c ac-
tivity of 680 mU/mg against phosphorylase, which is higher
than that obtained with baculovirus expressed PP4 (150 mU/
mg). From the level of PP4 (7 mg/kg tissue), it can be esti-
mated that the intracellular concentration of PP4 is 0.4 WM in
testis, which compares to about 1 WM for PP2A in skeletal
muscle [18]. However, although immunoblotting shows that
PP2A levels are fairly similar in most tissues, PP4 is approx-
imately ¢ve-fold less abundant in liver and 20-fold less abun-
dant in skeletal muscle than in testis (data not shown) indicat-
ing that the ratio of PP4/PP2A may be approximately 1/10 in
liver and 1/50 in skeletal muscle.
Lack of expression of soluble active PP4 in E. coli may be
either because a chaperone is required to fold the nascent
protein as observed for PP1 [20] or because post-translational
modi¢cation is essential. PP4, like PP2A, terminates in the
sequence DYFL. The C-terminal leucine is carboxymethylated
in PP2A [34,35] and PP4 [33]. Although this modi¢cation does
not appear to be essential for activity in PP2A, it is possible
that it is required for protein folding. Alternatively, carbox-
ymethylation may in£uence interactions with regulatory sub-
units. Partial puri¢cation shows that, like PP2A, most of the
PP4 in tissue extracts is found in higher molecular mass com-
plexes (Hastie et al., unpublished data). However, fostriecin
inhibits the trimeric form of PP2A (these studies and [17])
similarly to the catalytic subunit of PP2A, and therefore it
is extremely likely that the complexed forms of PP4 will be
inhibited similarly to the free PP4 catalytic subunit.
Since several tumour suppressors and promoters inhibit
PP4, it is relevant to consider whether any neoplasms show
alterations that could involve the PP4 gene at 16p11.2 (this
paper and [28,36]). Liposarcomas mapping to 16p11 have
been shown to result from translocations involving the FUS
transcription factor gene, mapping to this location [37]. Other
less common rearrangements at 16p11 have only been re-
ported in sporadic neoplasms [38].
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